Quick Answer
Niagen Bioscience, Inc. reported Total Revenue of $129.42 million for the year ending 2025.
- Niagen Bioscience, Inc. showed an increase of +29.9% in Total Revenue from 2024 to 2025.
- This data is from Niagen Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $2.03 million | Q2 2011: $1.94 million | Q2 2017: $4.22 million | Q3 2017: $6.08 million | Q1 2018: $6.57 million | Q2 2018: $7.80 million | Q3 2018: $8.12 million | Q1 2019: $10.05 million | Q2 2019: $11.10 million | Q3 2019: $12.05 million | Q1 2020: $14.35 million | Q2 2020: $15.29 million | Q3 2020: $14.18 million | Q1 2021: $14.68 million | Q2 2021: $17.70 million | Q3 2021: $17.31 million | Q1 2022: $17.26 million | Q2 2022: $16.73 million | Q3 2022: $17.06 million | Q1 2023: $22.56 million | Q2 2023: $20.32 million | Q3 2023: $19.50 million | Q1 2024: $22.15 million | Q2 2024: $22.74 million | Q3 2024: $25.58 million | Q1 2025: $30.48 million | Q2 2025: $31.12 million | Q3 2025: $33.99 million.
- Over the full 9 years of available data (2017 to 2025), Niagen Bioscience, Inc.'s Total Revenue has grown by 510.5%.
- Historical annual values: Fiscal year 2025: $129.42 million | Fiscal year 2024: $99.60 million | Fiscal year 2023: $83.57 million | Fiscal year 2022: $72.05 million | Fiscal year 2021: $67.45 million | Fiscal year 2020: $59.26 million | Fiscal year 2019: $46.29 million | Fiscal year 2018: $31.56 million | Fiscal year 2017: $21.20 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: